The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement

被引:87
作者
Campbell, J
Seymour, JF
Matthews, J
Wolf, M
Stone, J
Juneja, S
机构
[1] Royal Childrens Hosp, Dept Diagnost Haematol, Parkville, Vic 3052, Australia
[2] Royal Childrens Hosp, Div Lab Serv, Parkville, Vic 3052, Australia
[3] Peter MacCallum Canc Ctr, Dept Haematol & Med Oncol, Melbourne, Vic, Australia
[4] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
关键词
diffuse large cell lymphoma; bone marrow involvement; prognosis; discordant histology;
D O I
10.1111/j.1600-0609.2006.00644.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The prognostic significance of marrow involvement in diffuse large cell lymphoma (DLCL) is controversial. Factors that that have been reported to influence prognosis include the pattern and extent of marrow infiltration and histological discordance between the primary site and the bone marrow. Methods: Bone marrow biopsies from 172 patients with newly diagnosed DLCL entered in two consecutive trials of the Australasian Leukaemia and Lymphoma Group were analyzed. Progression-free (PFS) and overall survival (OS) were calculated according to the absence or presence of bone marrow involvement (BMI), the extent of lymphomatous infiltration and the presence of histological discordance between the primary site and the bone marrow. Results: Of 172 patients with DLCL accrued between 1982 and 1990, who were treated with CHOP or CHOP-like regimens, 47 (27%) demonstrated marrow involvement on examination of multiple levels. Seventy two percent (34/47) of patients had discordant marrow involvement (< 50% large cells) and 28 had minimal (< 10%) involvement; these latter patients with minimal marrow involvement (< 10%) had similar PFS & OS to the 113 patients without involvement. Within the group of 47 patients with marrow involvement, an increasing percentage of BM involvement was significantly associated with an increasing percentage of concordant histology and a decreasing PFS & OS. Conclusions: Minimal BMI, seen in the majority of patients with DLCL with marrow infiltration, appears not to influence the PFS & OS. However, an increasing degree of marrow involvement is associated with an increasing component of large cells and a poorer prognosis in DLCL patients, independent of other risk factors.
引用
收藏
页码:473 / 480
页数:8
相关论文
共 28 条
  • [1] LYMPHOPROLIFERATIONS IN THE BONE-MARROW - IDENTIFICATION AND EVOLUTION - CLASSIFICATION AND STAGING
    BARTL, R
    FRISCH, B
    BURKHARDT, R
    JAGER, K
    PAPPENBERGER, R
    HOFFMANNFEZER, G
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1984, 37 (03) : 233 - 254
  • [2] CABANILLAS F, 1992, BLOOD, V79, P1024
  • [3] Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma
    Campbell, JK
    Matthews, JP
    Seymour, JF
    Wolf, MM
    Juneja, SK
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (02) : 273 - 276
  • [4] CARBONE PP, 1971, CANCER RES, V31, P1860
  • [5] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
    Cheson, BD
    Horning, SJ
    Coiffier, B
    Shipp, MA
    Fisher, RI
    Connors, JM
    Lister, TA
    Vose, J
    Grillo-López, A
    Hagenbeek, A
    Cabanillas, F
    Klippensten, D
    Hiddemann, W
    Castellino, R
    Harris, NL
    Armitage, JO
    Carter, W
    Hoppe, R
    Canellos, GP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1244 - 1253
  • [6] FREQUENCIES AND PATTERNS OF BONE-MARROW INVOLVEMENT IN NON-HODGKIN LYMPHOMAS - OBSERVATIONS ON VALUE OF BILATERAL BIOPSIES
    COLLER, BS
    CHABNER, BA
    GRALNICK, HR
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 1977, 3 : 105 - 119
  • [7] BONE-MARROW INVOLVEMENT BY NON-HODGKINS-LYMPHOMA - THE CLINICAL-SIGNIFICANCE OF MORPHOLOGICAL DISCORDANCE BETWEEN THE LYMPH-NODE AND BONE-MARROW
    CONLAN, MG
    BAST, M
    ARMITAGE, JO
    WEISENBURGER, DD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) : 1163 - 1172
  • [8] RANDOMIZED COMPARISON OF MACOP-B WITH CHOP IN PATIENTS WITH INTERMEDIATE-GRADE NON-HODGKINS-LYMPHOMA
    COOPER, IA
    WOLF, MM
    ROBERTSON, TI
    FOX, RM
    MATTHEWS, JP
    STONE, JM
    DING, JC
    DART, G
    MATTHEWS, J
    FIRKIN, FC
    LOWENTHAL, RM
    IRONSIDE, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) : 769 - 778
  • [9] *CYTEL SOFTW CORP, 2001, STATXACT 5 0 3
  • [10] FISHER DE, 1989, CANCER-AM CANCER SOC, V64, P1879, DOI 10.1002/1097-0142(19891101)64:9<1879::AID-CNCR2820640921>3.0.CO